BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $5
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $5
RBC Capital Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
GoodRx Holdings (GDRX) Receives a Buy From RBC Capital
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $16
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $16
Leerink Partners Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $12
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
GoodRx Holdings: A Buy Rating on Strong Long-Term Care Growth and Strategic Market Positioning
Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating
Progyny Stock Sinks 25% After Losing a Big Client. Why This Analyst Still Likes the Stock. -- Barrons.com
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
GoodRx Holdings Price Target Maintained With a $10.00/Share by RBC Capital
GoodRx Holdings Analyst Ratings
RBC Capital Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
RBC Capital Keeps Their Buy Rating on GoodRx Holdings (GDRX)
GoodRx Holdings: A Hold Rating Amid Mixed Performance and Market Challenges
Citigroup Maintains Buy on GoodRx Holdings, Lowers Price Target to $10
GoodRx Holdings Analyst Ratings
GoodRx Holdings (GDRX) Gets a Buy From TD Cowen